Decrease of Replicative Capacity of HIV Isolates after Genotypic Guided Change of Therapy

Journal of Medical Virology

Volumn 72, Issue 4, 2004, Pages 511-516

  Sarmati, L ^a   Nicastri, E ^b   Montano, M ^a   Dori, L ^a   Buonomini, A R ^a   D'Ettorre, G ^d   Gatti, F ^c   Parisi, S G ^c   Vallo, V ^d   Andreonil, M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

HAART; HIV drug resistance; Replication capacity

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CD4 ANTIGEN; PROTEINASE; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONVALESCENCE; CORRELATION ANALYSIS; DRUG SENSITIVITY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; NONHUMAN; PREVALENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STRAIN IDENTIFICATION; VIREMIA; VIRUS DETECTION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROVIRUSES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 10744223664     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20030     Document Type: Article

References (19)

1. Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, Bambara RA, Demeter LM. 2000. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol 74(18):8390-8401.
2. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy in HIV infected patients with detectable viremia. N Engl J Med 344:472-480.
3. Feng JY, Anderson KS. 1999. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 38: 9440-9448.
4. Gamarnik AV, Wrin T, Ziermann R, Huang W, Whitehurst N, Whitcomb JM, Petropoulus CJ, The ViroLogic Clinical Reference Laboratory. 2000. Drug resistance is associated with impaired protease and reverse transcriptase function and reduced replication capacity: Characterization of recombinant viruses derived from 150 HIV-1 infected patients. 4th International Workshop on HIV Drug Resistance and Treatment Strategies. Sitges, Spain, 12-16 June 2000 [abstract 116]. Antivir Ther 5:S92.
5. Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, Demeter LM. 1999. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. J Virol 73(7):5803-5813.
6. Goetz MB, Moatamed F, Wrin T, Dawson K, Hellmann NS. 2002. Evolution of HIV fitness in patients maintained on a stable treatment regimen despite low-level virological failure [abstract H2059]. ICAAC. San Diego, CA. Unpublished data. PhenoSense; ViroLogic, Inc., San Francisco, CA, USA.
7. Grant RM, Barbour JD, Wrin T, Warmerdarm M, Hellmann NS, Kahn JO, Petropoulos CJ, Hecht FR. 2002. Transmission of drug resistant HIV-1 exhibiting lower replication capacity is associated with higher CD4 cell counts [abstract 46]. Abstracts of the XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. 2-5 July 2002, Seville, Spain. Antivir Ther 7:S53.
8. Haubrich R, Keiser P, Kemper K, Witt M, Leedom J, Forthal D, Leibowitz M, Hwang J, Seefried E, McCutchan JA, Hellmann N, Richman D, The CCTG Study Team. 2001. CCTG 575: A randomized, prospective study of phenotype testing versus standard of care for patients failing antiretroviral therapy [abstract 80]. 5th International Workshop on HIV Drug Resistance and Treatment Strategies. 4-8 June 2001, Scottsdale, AZ. Abstracts. Antivir Ther 6:S63.
9. Haubrich R, Wrin T, Hellmann N, McCutchan JA, Keiser P, Kemper C, Witt M, Leedom J, Forthal D, Richman D, The CCTG Study Team. 2002. Replication capacity (RC) as a predictor of immunologic and virologic benefit despite virologic failure of an antiretroviral regimen [abstract 121]. Abstracts of the XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. 2-5 July 2002, Seville, Spain. Antivir Ther 7:S133.
10. Hellmann N, Wrin T, Bates M, Grant R, Hicks C, Haubrich R, Petropoulos CJ. 2002. Modeling the effect of HIV replication capacity on treatment outcomes [abstract 63]. Abstracts of the XI International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications. 2-5 July 2002, Seville, Spain. Antivir Ther 7:S70.
11. Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, Andreoni M. 2003a. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virology 69:1-6.
12. Nicastri E, Sarmati L, d'Ettorre G, Parisi SG, Palmisano L, Galluzzo C, Uccella I, Amici R, Gatti F, Vullo V, Concia E, Vella S, Andreoni M. 2003b. Patients with viro-immunologic discordant response to HAART: High prevalence of M184V mutation and outcome after genotypic guided change of therapy. J Clin Microbiol 41:3007-3012.
13. Nijhuis M, Deeks S, Boucher C. 2001. Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis 14:23-28.
14. Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzetti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d'Arminio Manforte A, The Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group. 2001. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor - based therapy. J Infect Dis 184:983-991.
15. Schinazi RF, Larder BA, Mellors J. 2000. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antiviral News 8:65-91.
16. + cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: Immune response and viral control. J Infect Dis 187: 1027-1037.
17. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad VR. 1996a. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285.
18. Wainberg MA, Hsu M, Gu Z, Borkow G, Parniak MA. 1996b. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. AIDS 10:S3-S10.
19. Wrin T, Gamarnik AV, Whitehurst N, Beauchaine J, Whitcomb JM, Hellamann NS, Petropoulos CJ. 2001. Natural variation of replication capacity measurements in drug-naive/susceptible HIV-1. 5th International Workshop on HIV Drug Resistance and Treatment Strategies. 4-8 June 2001, Scottsdale, AZ [abstract 24]. Antivir Ther 6:S20.